Buying Genzyme Genetics, LabCorp Would Gain Its First Overseas Clinical Dx Foothold

The reference lab's planned acquisition of Genzyme Genetics, which would cost it around $800 billion, will give it its first foothold in a non-US market and will expand its genetic, hem-onc, and other esoteric plays.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.